In an attempt to pre-select ALS patients with an inflammatory profile, in the Tocilizumab (NCT02469896) and NP001 (NCT02794857) clinical trials, respectively, PBMC gene expression profiling and blood CRP levels were analyzed [146,147]. Here, CRP is linked to amyotrophic lateral sclerosis.